Diabetic Markers Market

Diabetic Markers Market Size and Share Forecast Outlook (2025 to 2035)

The Diabetic Markers Market is estimated to be valued at USD 1.1 billion in 2025 and is projected to reach USD 3.1 billion by 2035, registering a compound annual growth rate (CAGR) of 10.5% over the forecast period.

Quick Stats for Diabetic Markers Market

• Diabetic Markers Market Industry Value (2025): USD 1.1 billion
• Diabetic Markers Market Forecast Value (2035): USD 3.1 billion
• Diabetic Markers Market Forecast CAGR: 10.5%
• Leading Segment in Diabetic Markers Market in 2025: Traditional Biomarkers (48.7%)
• Key Growth Region in Diabetic Markers Market: North America, Asia-Pacific, Europe
• Top Key Players in Diabetic Markers Market: Tosoh Corporation, Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Bio-Rad Laboratories, Becton, Dickinson and Company, Sysmex Corporation, Ortho Clinical Diagnostics, Beckman Coulter, Randox Laboratories, DiaSys Diagnostic Systems, Trividia Health

Metric	Value
Diabetic Markers Market Estimated Value in (2025 E)	USD 1.1 billion
Diabetic Markers Market Forecast Value in (2035 F)	USD 3.1 billion
Forecast CAGR (2025 to 2035)	10.5%

Rationale for Segmental Growth in the Diabetic Markers Market

The diabetic markers market is expanding steadily as the prevalence of diabetes continues to rise globally, driven by lifestyle changes, aging populations, and increasing obesity rates. Growing demand for early diagnosis and monitoring of disease progression has heightened the adoption of biomarker-based testing solutions.

Advancements in molecular biology, immunoassays, and point of care diagnostics are further supporting market penetration by improving accuracy and turnaround times. Healthcare systems are prioritizing precision diagnostics to enable personalized treatment pathways and better patient outcomes.

Government initiatives aimed at reducing the burden of diabetes and technological innovations in laboratory testing have reinforced the adoption of diabetic markers. The outlook remains strong as research and clinical practices focus on integrating reliable markers into routine testing, thereby improving disease management and reducing long-term healthcare costs.

Segmental Analysis

Insights into the Traditional Biomarkers Segment

The traditional biomarkers segment is projected to hold 48.70% of the total revenue by 2025 within the biomarker category, making it the leading segment. This dominance is attributed to their established clinical utility, accessibility, and widespread integration into diagnostic protocols.

Traditional markers provide reliable and cost effective diagnostic outcomes, which have made them the cornerstone of diabetes detection and monitoring across healthcare systems.

The extensive body of supporting clinical evidence has reinforced their continued use in routine screening, thereby strengthening their leadership in the biomarker segment.

Insights into the Type 1 Diabetes Application Segment

The type 1 diabetes application segment is expected to account for 41.60% of total market revenue by 2025 within the application category, positioning it as the largest segment. The increasing prevalence of autoimmune related diabetes and rising awareness of early stage diagnosis are primary drivers of this growth.

Advancements in immunological and genetic testing have enabled more precise identification of disease onset, while healthcare campaigns emphasize early detection for improved disease management.

These factors have led to stronger adoption of markers specifically for type 1 diabetes, securing its position as the leading application segment.

Insights into the Hospitals End User Segment

The hospitals segment is projected to contribute 53.20% of total market revenue by 2025 within the end user category, making it the dominant segment. Hospitals remain the primary setting for diagnostic testing due to their access to advanced laboratory infrastructure, skilled professionals, and comprehensive patient care pathways.

The growing number of hospital based screening programs and integrated diabetes management units has further expanded demand. In addition, hospitals are increasingly adopting advanced biomarker assays as part of their precision medicine strategies, ensuring reliable diagnosis and effective patient monitoring.

This has reinforced their position as the leading end user segment in the diabetic markers market.

Comparison of Historical vs Future Outlook for Diabetic Markers Market (2020 to 2035)

From 2012 to 2025, the global diabetic markers market experienced a CAGR of 15.1%, reaching a market size of USD 1.1 million in 2025.

The increased prevalence of diabetes globally has propelled the diabetic markers market's historic expansion. Diabetes is a chronic metabolic illness characterized by high blood sugar levels, and its prevalence has progressively increased as a result of factors such as sedentary lifestyles, poor diets, and an ageing population. The expanding patient population has increased demand for diagnostic tools such as diabetes indicators, resulting in historic market growth.

The trend towards personalized therapy has contributed to the diabetes markers market's historic expansion. Personalised medicine is the practice of adapting treatment regimens to an individual's unique traits and genetic makeup. Diabetic marker, such as genetic testing and biomarkers, help in the identification of particular subtypes of diabetes, the prediction of disease progression, and the development of the most successful treatment regimens. Demand for diabetes indicators has increased due to the introduction of personalized treatment techniques.

Future Forecast for Diabetic Markers Industry:

Looking ahead, the global diabetic markers market is expected to rise at a CAGR of 11.0% from 2025 to 2035. During the forecast period, the market size is expected to reach USD 3.1 billion by 2035.

In the management of diabetes, there is a rising emphasis on early identification and intervention. Early identification enables immediate intervention and the application of lifestyle changes and medicines, thereby avoiding or postponing problems.

In the diabetes indicators market, the integration of digital health solutions and remote monitoring platforms is an emerging trend. Individuals with diabetes can use mobile health applications, cloud-based platforms, and remote monitoring devices to monitor their diabetic parameters, receive personalized feedback, and connect with healthcare specialists for virtual consultations. This trend makes data-driven diabetes care easier while also improving patient participation and results.

Analysis of Top Countries Adopting Diabetic Markers

What is Spurring the Growth of the USA Market?

Country	The United States
Market Size (USD Million) by End of Forecast Period (2035)	USD 3.1 million
CAGR % 2025 to End of Forecast (2035)	10.0%

The diabetic markers market in the United States is expected to reach a market size of USD 3.1 million by 2035, expanding at a CAGR of 10.0%. The prevalence of diabetes in the United States has been steadily rising over the years.

• According to the Centers for Disease Control and Prevention (CDC) 2025, approximately 34.2 million people in the USA have diabetes, and another 88 million have prediabetes.

The growing diabetic population creates a significant demand for diagnostic markers to aid in the diagnosis, monitoring, and management of the disease.

Diabetic Markers Market is Expected to Grow at a Significant Pace Owing to Growing Focus on Preventive Healthcare.

Country	The United Kingdom
Market Size (USD Million) by End of Forecast Period (2035)	USD 175.6 million
CAGR % 2025 to End of Forecast (2035)	8.2%

The diabetic markers market in the United Kingdom is expected to reach a market value of USD 175.6 million, expanding at a CAGR of 8.2% during the forecast period. There is a growing government initiatives and national diabetes programs. To combat the rising burden of diabetes, the United Kingdom government has developed a number of initiatives including national diabetes programs. These programs emphasize early illness detection, prevention, and better disease management. The use of diabetes indicators for screening, risk assessment, and personalized treatment methods is emphasized as part of these programs.

Why China is a Lucrative Market in East Asia Diabetic Markers Market?

Country	China
Market Size (USD Million) by End of Forecast Period (2035)	USD 326.1 million
CAGR % 2025 to End of Forecast (2035)	15.1%

The diabetic markers market in China is anticipated to reach a market size of USD 326.1 million by the end of 2035, growing at a CAGR of 15.1% throughout the forecast period. Significant research and development initiatives in the field of diabetes indicators have occurred in Japan. Academic institutions, research organisations, and industry participants all take an active role in the creation of novel markers and diagnostic technologies. Innovation is driven by research improvements and collaborations, which increase diagnosis accuracy and extend the market for diabetes indicators.

Rigorous Research and Development Efforts Have Led Japan to Develop and Innovate Novel Diabetic Markers.

Country	Japan
Market Size (USD Million) by End of Forecast Period (2035)	USD 203.0 million
CAGR % 2025 to End of Forecast (2035)	14.1%

The diabetic markers market in Japan is estimated to reach a market size of USD 203.0 million by 2035, expected to thrive at a CAGR of 14.1%. Significant research and development initiatives in the field of diabetes indicators have occurred in Japan. Academic institutions, research organisations, and industry participants all take an active role in the creation of novel markers and diagnostic technologies. Innovation is driven by research improvements and collaborations, which increase diagnosis accuracy and extend the market for diabetes indicators.

Demand for Diabetic Markers Market is Rising Due to Strong Healthcare Infrastructure.

Country	South Korea
Market Size (USD Million) by End of Forecast Period (2035)	USD 17.1 million
CAGR % 2025 to End of Forecast (2035)	18.2%

The diabetic markers market in South Korea is expected to reach a market size of USD 17.1 million, expanding at a CAGR of 18.2% during the forecast period. Diabetic indicators have become more accurate and efficient as diagnostic technology and inventions have advanced. South Korea has made tremendous progress in the development of diabetes biomarkers, genetic diagnostics, and point-of-care devices. Technological innovations propel the diabetes markers market forward by improving diagnostic capabilities and broadening the variety of accessible markers.

Diabetic Markers Industry Analysis by Category

Traditional Biomarkers to Dominate Diabetic Markers Industry with 57.8% Market Share in 2025

Traditional biomarkers dominated the diabetic markers market with a market share of 57.8% in 2025. Traditional biomarkers hemoglobin A1c (HbA1c) predict chronic glycaemia better than glucose levels at a single time point and are presently the most often utilized biomarkers for diagnosing prediabetes and diabetes. Traditional biomarkers to lead the demand have more convenience since avoiding food isn't essential, greater preanalytical stability, and less day-to-day disturbance during periods of stress and sickness.

Which Application is Predominantly in Demand in the Global Scenario?

Based on application, type 2 diabetes dominated the category withholding the significant share of the market at around 71.7% at the end of 2025. Diabetes mellitus type 2 (T2DM) is a common chronic condition that is connected with the development of complications. The potential application for the management of type 2 diabetes mellitus (T2DM) is a critical element assisting in the acceptance of T2DM biomarkers. The biomarkers have also been proven to be effective in detecting diabetes mellitus. As a result, the T2DM has the largest market share in the market.

Which End User Has Widely Adopted the Diabetic Markers?

The hospitals have led the diabetic markers market as the leading end user with the market share of 44.5% in 2025. Hospitals are the principal providers of acute care, serving a diverse variety of patients, including those suffering from chronic illnesses and other life-threatening disorders. Diabetic biomarkers have great clinical usefulness in these situations, assisting with diabetes mellitus diagnosis, monitoring, and treatment. Because hospitals rely on biomarkers to assist clinical decision-making, they are market leaders.

Competitive Landscape of the Diabetic Markers Market

Key players in the diabetic markers market can increase their competitiveness, differentiate their products, and maintain a strong market presence by implementing various growth strategies. In this competitive industry, long-term viability demands constant innovation, strategic alliances, efficient marketing, and strategies that prioritize clients.

Key Strategies Used by the Participants

• Product Innovation

Key players continuously invest in research and development to introduce innovative diabetic biomarker products. They strive to develop assays with improved sensitivity, specificity, accuracy, and ease of use.

• Strategic Partnerships and Collaborations

Key players often form strategic partnerships and collaborations with other companies, research institutions, and healthcare organizations. These partnerships can lead to knowledge sharing, joint product development, and expanded market reach.

• Expansion into Emerging Markets

Expanding into emerging markets with growing healthcare infrastructure and rising demand for diabetic biomarker allows companies to tap into new opportunities and gain a competitive edge.

• Mergers and Acquisitions

Companies in the market may engage in mergers or acquisitions to streamline their product portfolio, obtain new technologies, enter new market niches, and gain access to novel products or intellectual property.

Key Players in the Diabetic Markers Industry

• Tosoh Corporation
• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Bio-Rad Laboratories
• Becton, Dickinson and Company
• Sysmex Corporation
• Ortho Clinical Diagnostics
• Beckman Coulter
• Randox Laboratories
• DiaSys Diagnostic Systems
• Trividia Health

Key Developments in the Diabetic Markers Market:

• March, 2025. In a partnership that was launched, Roche and Bristol-Myers Squibb will enhance two tests for use in clinical trials through the creation and implementation of two novel digital pathology algorithms. The first test is VENTANA PD-L1 (SP142) Assay in which Bristol Myers Squibb will be involved in the generation of biomarker data from clinical trial samples.
• In June 2025, during a historic CES keynote, Abbott introduces a new category of biowearables. In order to provide consumers a greater understanding of their health and wellness, Abbott will measure important indicators in the body such glucose, ketones, lactate, and alcohol.

Segmentation Analysis of the Diabetic Markers Market

By Biomarker:

• Traditional Biomarkers
• Novel Biomarkers
• Inflammatory Biomarkers

By Application:

• Type 1 Diabetes
• Type 2 Diabetes

By End User:

• Hospitals
• Diagnostics Centers
• Specialty Clinics
• Academic and Research Institutes

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East & Africa